The Sanger (UK) and Broad (USA) Institutes joined efforts to generate a complete map of all cancer vulnerabilities to propose novel therapeutical targets (Cancer Dependency Map).
Harnessing the Cancer DepMap CRISPR-Cas9 and drug sensitivity screens across 484 cancer cell lines, we created a computational resource for 397 anti-cancer drugs that informs on many aspects of drug mode-of-action (i.e. in cellular activity, isoform specificity and potential polypharmacology effects).
The millions of associations tested allowed us to characterise protein networks underlying drug response and revealed novel regulatory interactions.